Retatrutide is a synthetic triple-receptor agonist peptide designed to engage GLP-1, GIP, and glucagon receptors in experimental systems
Tirzepatide is generally studied as a dual GIP and GLP-1 receptor agonist, while Retatrutide is studied as a triple receptor agonist involving GIP, GLP-1, and glucagon receptor pathways
Retatrutide 10mg The 10mg vial format of retatrutide, Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist, offering greater dosing flexibility for metabolic research protocols targeting weight loss, insulin resistance, and hepatic fat
$143.00 High-Stability Polypeptide for Laboratory Evaluation Technical Overview Retatrutide is a synthetic peptide engineered to interact with multiple metabolic receptor systems including GLP-1, GIP, and glucagon receptors
Manufactured to the highest industry standards, each batch undergoes rigorous testing to ensure unmatched purity, potency, and consistencymaking it ideal for comprehensive scientific research and reliable outcomes
Minimize exposure to heat, humidity, and direct light
